According to Fortune Business Insights, the global vaccines market size was valued at USD 88.92 billion in 2025 and is projected to grow from USD 95.68 billion in 2026 to USD 227.89 billion by 2034, exhibiting a Compound Annual Growth Rate (CAGR) of 11.46% during the forecast period.
The vaccines market is expected to experience significant growth due to increasing immunization programs, rising awareness regarding preventive healthcare, growing investments in vaccine research and development, and the increasing burden of infectious diseases. Vaccination continues to be one of the most effective approaches for preventing infectious diseases and reducing healthcare costs associated with disease treatment and complications. Governments, healthcare organizations, and international health agencies are strengthening immunization initiatives, which is creating favorable opportunities for the vaccines market. The development of advanced vaccine technologies, including recombinant vaccines, conjugate vaccines, messenger RNA-based vaccines, and other innovative platforms, is also supporting market expansion. The vaccines market is further benefiting from increased investments by pharmaceutical and biotechnology companies in the development of preventive and therapeutic vaccines. According to the provided market data, North America dominated the vaccines market in 2025 with a market share of 11.46%. The region benefits from advanced healthcare infrastructure, strong research capabilities, high healthcare expenditure, established vaccination programs, and the presence of major pharmaceutical companies.
Continue reading for more details:
https://www.fortunebusinessinsights.com/industry-reports/vaccines-market-101769
The vaccines market can be segmented based on type, technology, route of administration, disease indication, age group, and geography. By type, the vaccines market includes recombinant/conjugate vaccines, live attenuated vaccines, inactivated vaccines, mRNA vaccines, and other vaccine types. Recombinant and conjugate vaccines have gained considerable adoption because of their effectiveness in preventing several infectious diseases, while mRNA vaccine technology has created new opportunities for rapid vaccine development and innovation. By technology, the vaccines market is categorized into conjugate vaccines, recombinant vaccines, and other advanced technologies. Technological advancements are enabling manufacturers to develop vaccines with improved efficacy, safety profiles, and production capabilities. By route of administration, the vaccines market includes injectable and other administration routes. Injectable vaccines remain widely adopted because of their established delivery methods and extensive use across routine immunization programs. Based on disease indication, the vaccines market covers infectious diseases such as influenza, pneumococcal disease, human papillomavirus, hepatitis, meningitis, and other indications. The growing incidence of infectious diseases and increasing vaccination coverage are supporting demand across multiple disease categories. By age group, the market includes pediatric and adult populations. Pediatric vaccination represents a major segment due to mandatory and routine childhood immunization programs, while adult vaccination is gaining importance because of increasing awareness regarding preventive healthcare and vaccination against age-related and infectious diseases.
The vaccines market is projected to expand from USD 95.68 billion in 2026 to USD 227.89 billion by 2034, registering a CAGR of 11.46% during the forecast period. One of the primary factors supporting vaccines market growth is the increasing emphasis on preventive healthcare. Healthcare systems worldwide are focusing on preventing diseases rather than relying solely on treatment, encouraging governments and healthcare providers to increase vaccination coverage. National immunization programs and government-funded vaccination campaigns are creating consistent demand for vaccines across both developed and emerging economies. Increasing awareness among consumers regarding the benefits of vaccination is also contributing to vaccines market growth. Parents are increasingly seeking routine childhood immunization, while adults are becoming more aware of vaccines recommended for seasonal infections, travel-related diseases, and age-associated health risks. The growing elderly population is expected to create additional opportunities because older adults are more vulnerable to certain infectious diseases and complications. Another major factor supporting the vaccines market is the rising investment in research and development. Pharmaceutical and biotechnology companies are investing in innovative vaccine platforms designed to improve protection, shorten development timelines, and address emerging infectious diseases. The development of mRNA technology has demonstrated the potential for rapid vaccine design and is encouraging further research into vaccines for infectious diseases and other medical applications. Expanding healthcare infrastructure in emerging countries is also supporting vaccines market growth. Improvements in healthcare accessibility, cold-chain infrastructure, diagnostic capabilities, and immunization delivery systems are enabling more individuals to receive vaccines. In addition, partnerships between governments, pharmaceutical companies, research institutions, and healthcare organizations are accelerating vaccine development and distribution. Growing concerns regarding future disease outbreaks are encouraging countries to strengthen vaccine manufacturing capacity and maintain preparedness programs. These developments are expected to support sustained expansion of the vaccines market throughout the forecast period.